Reported Sildenafil Side Effects in Pediatric Pulmonary Hypertension Patients

Background: Sildenafil, a phosphodiestase type 5 inhibitor, was approved in 2005 for the treatment of pulmonary arterial hypertension (PAH) in adults and is commonly used off-label for pediatric patients. Little is known, however, about sildenafil’s side effects in this population. Methods: Single i...

Descripción completa

Detalles Bibliográficos
Autores principales: Siehr, Stephanie L., McCarthy, Elisa K., Ogawa, Michelle T., Feinstein, Jeffrey A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353247/
https://www.ncbi.nlm.nih.gov/pubmed/25806361
http://dx.doi.org/10.3389/fped.2015.00012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353247/
https://www.ncbi.nlm.nih.gov/pubmed/25806361
http://dx.doi.org/10.3389/fped.2015.00012

Ejemplares similares